Trial Profile
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Ranibizumab
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 29 Sep 2014 New trial record